Exclusive Summary

• - Core patents/exclusivities have expired (US ~2016; EU post-2018 with SPCs ending ~2022–2024), enabling broad Distribution entry worldwide.
• - Stable hospital demand: ~0.7–1.0 million invasive candidiasis cases/year globally, ~90–100k HSCT/year, and 1.5–2.0 million HIV-related esophageal candidiasis episodes.
• - Echinocandins are guideline-recommended first-line; micafungin has strong evidence for candidemia/IC treatment and HSCT prophylaxis with once-daily dosing and few interactions.
• - Generics typically discount 40–80% vs brand; the 50 mg vial aligns with HSCT prophylaxis dosing to reduce wastage and daily treatment cost.
• - Despite many competitors, geographic and channel gaps remain; SRA-grade compliance and proven registration track-record create procurement differentiation.